Drug intelligence / Profile preview

simvastatin + zoledronic acid

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Simvastatin + zoledronic acid is a combination therapy that creates a sequential blockade of the mevalonate pathway. Simvastatin inhibits HMG-CoA reductase, while zoledronic acid inhibits farnesyl pyrophosphate synthase. This combination has shown synergistic effects in inducing apoptosis in cancer cells, suppressing Dickkopf-1 in breast cancer, and treating parasitic infections like toxoplasmosis. The synergy allows for lower concentrations of each drug to be used while maintaining or enhancing efficacy.

Brand names: ZocorZometa
Other names: Simvastatin and zoledronic acid combination

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)FDPS (Farnesyl pyrophosphate synthase)

Beyond the preview

Go deeper on simvastatin + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on simvastatin + zoledronic acid.

Explore the full profile